Tags

Type your tag names separated by a space and hit enter

[Safety and efficacy of an antirabies vaccine consisting of recombinant vaccinia-rabies virus administered orally to the fox, dog and cat].
Ann Rech Vet. 1989; 20(2):195-204.AR

Abstract

One of the most promising ways to control rabies in wildlife seems to be the distribution of bait containing an anti-rabies vaccine. So far, the most widely used vaccines were modified live viruses (SAD strain or derivatives). Nevertheless, these strains retain some pathogenicity for non-target species. A novel vaccine was proposed consisting of genetically modified vaccinia virus (strain Copenhagen, thermosensitive ts 26) expressing the foreign glycoprotein G for the rabies virus (strain ERA). Different doses of this recombinant virus were administered orally to 59 foxes (Vulpes vulpes) and their antibodies were titrated before challenge. Foxes (8/8) resisted 1 month after vaccination with 10(7) plaque forming units (PFU), or 4/4 after 18 months. Seroconversion among dogs was 4/4 after vaccination with 10(9,6) PFU and 4/4 among cats after vaccination with 10(8) PFU. These dogs (4/4) and cats (3/4) resisted the challenge 2-3 months after vaccination. This vaccine thus appears to be potent and safe in these species. Its properties are discussed.

Authors+Show Affiliations

CNEVA, Laboratoire d'Etudes sur la Rage et la Pathologie des Animaux Sauvages, Malzéville, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

2751231

Citation

Blancou, J, et al. "[Safety and Efficacy of an Antirabies Vaccine Consisting of Recombinant Vaccinia-rabies Virus Administered Orally to the Fox, Dog and Cat]." Annales De Recherches Veterinaires. Annals of Veterinary Research, vol. 20, no. 2, 1989, pp. 195-204.
Blancou J, Artois M, Brochier B, et al. [Safety and efficacy of an antirabies vaccine consisting of recombinant vaccinia-rabies virus administered orally to the fox, dog and cat]. Ann Rech Vet. 1989;20(2):195-204.
Blancou, J., Artois, M., Brochier, B., Thomas, I., Pastoret, P. P., Desmettre, P., Languet, B., & Kiény, M. P. (1989). [Safety and efficacy of an antirabies vaccine consisting of recombinant vaccinia-rabies virus administered orally to the fox, dog and cat]. Annales De Recherches Veterinaires. Annals of Veterinary Research, 20(2), 195-204.
Blancou J, et al. [Safety and Efficacy of an Antirabies Vaccine Consisting of Recombinant Vaccinia-rabies Virus Administered Orally to the Fox, Dog and Cat]. Ann Rech Vet. 1989;20(2):195-204. PubMed PMID: 2751231.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Safety and efficacy of an antirabies vaccine consisting of recombinant vaccinia-rabies virus administered orally to the fox, dog and cat]. AU - Blancou,J, AU - Artois,M, AU - Brochier,B, AU - Thomas,I, AU - Pastoret,P P, AU - Desmettre,P, AU - Languet,B, AU - Kiény,M P, PY - 1989/1/1/pubmed PY - 1989/1/1/medline PY - 1989/1/1/entrez SP - 195 EP - 204 JF - Annales de recherches veterinaires. Annals of veterinary research JO - Ann Rech Vet VL - 20 IS - 2 N2 - One of the most promising ways to control rabies in wildlife seems to be the distribution of bait containing an anti-rabies vaccine. So far, the most widely used vaccines were modified live viruses (SAD strain or derivatives). Nevertheless, these strains retain some pathogenicity for non-target species. A novel vaccine was proposed consisting of genetically modified vaccinia virus (strain Copenhagen, thermosensitive ts 26) expressing the foreign glycoprotein G for the rabies virus (strain ERA). Different doses of this recombinant virus were administered orally to 59 foxes (Vulpes vulpes) and their antibodies were titrated before challenge. Foxes (8/8) resisted 1 month after vaccination with 10(7) plaque forming units (PFU), or 4/4 after 18 months. Seroconversion among dogs was 4/4 after vaccination with 10(9,6) PFU and 4/4 among cats after vaccination with 10(8) PFU. These dogs (4/4) and cats (3/4) resisted the challenge 2-3 months after vaccination. This vaccine thus appears to be potent and safe in these species. Its properties are discussed. SN - 0003-4193 UR - https://www.unboundmedicine.com/medline/citation/2751231/[Safety_and_efficacy_of_an_antirabies_vaccine_consisting_of_recombinant_vaccinia_rabies_virus_administered_orally_to_the_fox_dog_and_cat]_ L2 - https://medlineplus.gov/rabies.html DB - PRIME DP - Unbound Medicine ER -